S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
S&P 500   2,472.65 (-4.33%)
DOW   21,025.66 (-4.07%)
QQQ   183.62 (-3.56%)
AAPL   243.49 (-4.25%)
FB   160.42 (-3.82%)
MSFT   152.91 (-3.04%)
GOOGL   1,109.47 (-4.52%)
AMZN   1,908.35 (-2.12%)
CGC   13.56 (-6.03%)
NVDA   251.96 (-4.42%)
BABA   187.19 (-3.75%)
MU   40.23 (-4.35%)
GE   7.19 (-9.33%)
TSLA   495.32 (-5.47%)
AMD   44.56 (-2.02%)
T   27.95 (-4.12%)
F   4.43 (-8.48%)
NFLX   362.34 (-3.50%)
BAC   19.76 (-6.97%)
GILD   72.89 (-2.50%)
PRI   83.89 (-5.69%)
DIS   94.73 (-1.94%)
Log in

NASDAQ:LOGC - LogicBio Therapeutics Stock Price, Forecast & News

$4.28
-0.66 (-13.36 %)
(As of 04/1/2020 02:44 PM ET)
Today's Range
$4.27
Now: $4.28
$5.32
50-Day Range
$4.06
MA: $7.20
$10.45
52-Week Range
$3.05
Now: $4.28
$20.07
Volume4,240 shs
Average Volume75,380 shs
Market Capitalization$98.10 million
P/E RatioN/A
Dividend YieldN/A
Beta0.98
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. The company has a partnership with Children's Medical Research Institute to develop new viral vectors. LogicBio Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LOGC
CUSIPN/A
CIKN/A
Phone617-245-0399

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.84 per share

Profitability

Net Income$-40,130,000.00

Miscellaneous

Employees23
Market Cap$98.10 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive LOGC News and Ratings via Email

Sign-up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter.


LogicBio Therapeutics (NASDAQ:LOGC) Frequently Asked Questions

How has LogicBio Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

LogicBio Therapeutics' stock was trading at $7.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LOGC stock has decreased by 39.2% and is now trading at $4.28. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of LogicBio Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LogicBio Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for LogicBio Therapeutics.

When is LogicBio Therapeutics' next earnings date?

LogicBio Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for LogicBio Therapeutics.

How were LogicBio Therapeutics' earnings last quarter?

LogicBio Therapeutics Inc (NASDAQ:LOGC) released its quarterly earnings data on Monday, March, 16th. The company reported ($0.51) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.49) by $0.02. View LogicBio Therapeutics' earnings history.

What price target have analysts set for LOGC?

3 analysts have issued 1 year price objectives for LogicBio Therapeutics' shares. Their forecasts range from $20.00 to $26.00. On average, they anticipate LogicBio Therapeutics' share price to reach $23.00 in the next year. This suggests a possible upside of 437.4% from the stock's current price. View analysts' price targets for LogicBio Therapeutics.

What are Wall Street analysts saying about LogicBio Therapeutics stock?

Here are some recent quotes from research analysts about LogicBio Therapeutics stock:
  • 1. According to Zacks Investment Research, "LogicBio Therapeutics Inc. is a genome editing company. It focuses on developing medicines to treat rare diseases in patients with significant unmet medical needs. The company's technology platform consists of GeneRide(TM). LogicBio Therapeutics Inc. is based in Cambridge, Massachusetts. " (11/14/2019)
  • 2. Chardan Capital analysts commented, "We see limited read-across on nuclease-free editing controversy On 21 July, researchers from the California posted a manuscript to the bioRxiv preprint server outlining outlining unsuccessful efforts to reproduce efficient nuclease-free genome editing with clade F AAV vectors, based on a 2018 publication from Homology Medicines (unrated), which reported >50% editing with similar AAV vectors isolated from hematopoietic stem cells (AAVHSCs). Increasing attention drawn to the preprint to us may have sent Homology’s share price down >20% by the market close on July 25th. Below, we highlight some considerations for interpreting the data and the extent of potential read-across for other companies in the space." (7/29/2019)

Has LogicBio Therapeutics been receiving favorable news coverage?

Headlines about LOGC stock have been trending extremely negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. LogicBio Therapeutics earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutLogicBio Therapeutics.

Who are some of LogicBio Therapeutics' key competitors?

What other stocks do shareholders of LogicBio Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LogicBio Therapeutics investors own include Editas Medicine (EDIT), Acceleron Pharma (XLRN), Alector (ALEC), Gossamer Bio (GOSS), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Kaleido Biosciences (KLDO), Bristol-Myers Squibb (BMY), Pfizer (PFE) and NVIDIA (NVDA).

Who are LogicBio Therapeutics' key executives?

LogicBio Therapeutics' management team includes the following people:
  • Mr. Frederic Chereau, Pres, CEO & Director (Age 52)
  • Mr. Matthias B. Jaffé, Chief Financial Officer (Age 50)
  • Mr. Tom Wilton, Chief Bus. Officer (Age 45)
  • Dr. Leszek Lisowski Ph.D., Co-Founder
  • Dr. Adi Barzel, Co-Founder

When did LogicBio Therapeutics IPO?

(LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

What is LogicBio Therapeutics' stock symbol?

LogicBio Therapeutics trades on the NASDAQ under the ticker symbol "LOGC."

How do I buy shares of LogicBio Therapeutics?

Shares of LOGC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is LogicBio Therapeutics' stock price today?

One share of LOGC stock can currently be purchased for approximately $4.28.

How big of a company is LogicBio Therapeutics?

LogicBio Therapeutics has a market capitalization of $98.10 million. The company earns $-40,130,000.00 in net income (profit) each year or ($1.78) on an earnings per share basis. LogicBio Therapeutics employs 23 workers across the globe. View additional information about LogicBio Therapeutics.

What is LogicBio Therapeutics' official website?

The official website for LogicBio Therapeutics is http://www.logicbio.com/.

How can I contact LogicBio Therapeutics?

LogicBio Therapeutics' mailing address is 99 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-245-0399 or via email at [email protected]


MarketBeat Community Rating for LogicBio Therapeutics (NASDAQ LOGC)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  67 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  146
MarketBeat's community ratings are surveys of what our community members think about LogicBio Therapeutics and other stocks. Vote "Outperform" if you believe LOGC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LOGC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel